Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmGlobeNewsWire • Monday
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and NeurodegenerationBusiness Wire • 08/12/24
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024Business Wire • 08/05/24
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram SyndromeBusiness Wire • 08/02/24
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call TranscriptSeeking Alpha • 07/10/24
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy DesignationBusiness Wire • 07/10/24
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of AvexitideBusiness Wire • 07/09/24
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 AcquisitionSeeking Alpha • 06/25/24
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 06/04/24
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/09/24
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care ConferenceBusiness Wire • 05/08/24
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024Business Wire • 05/02/24
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeBusiness Wire • 04/10/24
April 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AMLXAccesswire • 04/09/24
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLXAccesswire • 04/09/24
Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming DeadlineAccesswire • 04/09/24
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 04/09/24
The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXPRNewsWire • 04/09/24